Urolithiasis pp 611-618 | Cite as

The Effect of Normal and Stone-Forming Urine on the Growth and Aggregation of Calcium Oxalate Crystals in Relation to Urinary Glycosaminoglycan and Urate Concentrations

  • R. L. Ryall
  • V. R. Marshall


The factors which play a determinant role in urinary stone formation can be broadly classified into two main categories — those affecting the supersaturation of the urine with respect to the precipitating salt, and those which influence the ability of the urine to inhibit crystal nucleation, growth and aggregation. The supersaturation of urine with calcium oxalate is principally a function of calcium and oxalate excretion1 and urinary pH, while inhibitory activity has been attributed to the presence of pyrophosphate and glycosaminoglycans (GAGS)2. For some years uric acid has been implicated in calcium oxalate stone formation3 by virtue of its effect on calcium oxalate solubility4 and the capability of its sodium salt of inducing heterogeneous nucleation of calcium oxalate. More recently2 it has been proposed that uric acid can indirectly predispose to calcium oxalate stone formation by interacting with urinary GAGS, thereby reducing their inhibitory capacity. Although it is widely accepted that urine can strongly inhibit crystal growth and aggregation, the significant reduction6 of this activity in urine from stone-formers compared with normal subjects has not been confirmed7.


Uric Acid Calcium Oxalate Initial Reaction Rate Uric Acid Concentration Calcium Oxalate Crystal 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    H. Fleisch, Kid. Int. 13:361 (1978).CrossRefGoogle Scholar
  2. 2.
    W. G. Robertson, F. Knowles, and M. Peacock, in: “Urolithiasis Research,” H. Fleisch, W. G. Robertson, L. H. Smith, and W. Vahlensieck, eds. Plenum Press, New York/London (1976).Google Scholar
  3. 3.
    F. L. Coe, Kid. Int. 13:418 (1978).CrossRefGoogle Scholar
  4. 4.
    W. G. Robertson, M. Peacock, and B. E. C. Nordin, Clin. Sci. 40:365 (1971).PubMedGoogle Scholar
  5. 5.
    F. L. Coe, R. L. Lawton, R. B. Goldstein, and V. Tembe, Proc. Soc. Exp. Biol. Med. 149:926 (1975).PubMedGoogle Scholar
  6. 6.
    W. G. Robertson and M. Peacock, Clin. Sci. 43:499 (1972).PubMedGoogle Scholar
  7. 7.
    J. M. Baumann, S. Bisaz, R. Felix, H. Fleisch, U. Ganz, and R. G. G. Russel, Clin. Sci. Mol. Med. 53:141 (1977).PubMedGoogle Scholar
  8. 8.
    R. L. Ryall and V. R. Marshall. These proceedings.Google Scholar
  9. 9.
    N. A. C. Cressie and D. D. Keightley, J. Steroid Biochem. 11:1173 (1979).PubMedCrossRefGoogle Scholar
  10. 10.
    C. J. Farrington and A. H. Chalmers, Clin. Chem. 25:1993 (1979).Google Scholar
  11. 11.
    N. Blumenkrantz and G. Asboe-Hansen, Anal. Biochem. 54:484 (1973).PubMedCrossRefGoogle Scholar
  12. 12.
    D. V. Weber, F. L. Coe, J. H. Parks, M. S. L. Dunn, and V. Tembe, Ann. Int. Med. 90:180 (1979).PubMedGoogle Scholar
  13. 13.
    W. G. Robertson, M. Peacock, P. J. Heyburn, D. H. Marshall, and P. B. Clark, Br. J. Urol. 50:449 (1978).PubMedCrossRefGoogle Scholar
  14. 14.
    R. L. Ryall, R. G. Ryall, and V. R. Marshall, in: “Proceedings International Urinary Stone Conference, Perth,” J. G. Brockis and B. Finlayson, eds., PSG Publishing Company, Littleton, Connecticut (in press).Google Scholar
  15. 15.
    T. C. Laurent, Nature 202:1334 (1964).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1981

Authors and Affiliations

  • R. L. Ryall
    • 1
  • V. R. Marshall
    • 1
  1. 1.Urology Unit, Department of SurgeryFlinders Medical CenterBedford ParkSouth AustraliaAustralia

Personalised recommendations